JP4902544B2 - ラモトリジンの免疫アッセイ - Google Patents

ラモトリジンの免疫アッセイ Download PDF

Info

Publication number
JP4902544B2
JP4902544B2 JP2007539029A JP2007539029A JP4902544B2 JP 4902544 B2 JP4902544 B2 JP 4902544B2 JP 2007539029 A JP2007539029 A JP 2007539029A JP 2007539029 A JP2007539029 A JP 2007539029A JP 4902544 B2 JP4902544 B2 JP 4902544B2
Authority
JP
Japan
Prior art keywords
lamotrigine
antibody
analog
enzyme
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007539029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518234A (ja
JP2008518234A5 (US07678551-20100316-C00001.png
Inventor
オウヤン，アンロン
アラバシャヒ，リリ
ロバーツ，マーク
ウォール，メリッサ
Original Assignee
セラダイン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラダイン，インコーポレーテッド filed Critical セラダイン，インコーポレーテッド
Publication of JP2008518234A publication Critical patent/JP2008518234A/ja
Publication of JP2008518234A5 publication Critical patent/JP2008518234A5/ja
Application granted granted Critical
Publication of JP4902544B2 publication Critical patent/JP4902544B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9473—Anticonvulsants, e.g. phenobarbitol, phenytoin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/13—Tracers or tags
JP2007539029A 2004-10-25 2005-10-21 ラモトリジンの免疫アッセイ Expired - Fee Related JP4902544B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62176404P 2004-10-25 2004-10-25
US60/621,764 2004-10-25
US11/254,637 2005-10-20
US11/254,637 US7678551B2 (en) 2004-10-25 2005-10-20 Immunoassays for lamotrigine
PCT/US2005/038258 WO2006047451A2 (en) 2004-10-25 2005-10-21 Immunoassays for lamotrigine

Publications (3)

Publication Number Publication Date
JP2008518234A JP2008518234A (ja) 2008-05-29
JP2008518234A5 JP2008518234A5 (US07678551-20100316-C00001.png) 2008-07-10
JP4902544B2 true JP4902544B2 (ja) 2012-03-21

Family

ID=36228347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539029A Expired - Fee Related JP4902544B2 (ja) 2004-10-25 2005-10-21 ラモトリジンの免疫アッセイ

Country Status (6)

Country Link
US (2) US7678551B2 (US07678551-20100316-C00001.png)
EP (1) EP1805515B1 (US07678551-20100316-C00001.png)
JP (1) JP4902544B2 (US07678551-20100316-C00001.png)
AU (1) AU2005299537B2 (US07678551-20100316-C00001.png)
CA (1) CA2586511C (US07678551-20100316-C00001.png)
WO (1) WO2006047451A2 (US07678551-20100316-C00001.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2239573A3 (en) * 2005-03-30 2011-02-08 Saladax Biomedical Inc. Doxorubicin derivatives and conjugates for doxorubicin immunoassay
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
EP2596805B1 (en) * 2008-02-01 2021-10-27 Ascendis Pharma A/S Prodrug comprising a drug-linker conjugate
KR101799113B1 (ko) 2009-05-13 2017-11-17 넥타르 테라퓨틱스 올리고머를 함유하는 치환된 방향족 트리아진 화합물
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
PE20120918A1 (es) 2009-07-31 2012-08-14 Sanofi Aventis Deutschland Profarmacos que comprenden un conjugado de insulina-conector
RU2556340C2 (ru) 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Композиция инсулина длительного действия
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US9726681B2 (en) * 2013-08-07 2017-08-08 Siemens Healthcare Diagnostics Inc. Compositions and methods for detecting cortisol
WO2015092819A2 (en) * 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
CN108840933A (zh) * 2018-07-16 2018-11-20 夏泉 一种拉莫三嗪单克隆抗体的制备方法
CN108918851B (zh) * 2018-07-16 2020-04-07 夏泉 一种拉莫三嗪胶体金试纸条的制备方法
JP7077175B2 (ja) * 2018-08-07 2022-05-30 キヤノン株式会社 自動分析装置、自動分析方法、および、プログラム
CN110967481B (zh) * 2019-12-06 2023-07-04 苏州博源医疗科技有限公司 一种拉莫三嗪衍生物、其制备方法及其在均相酶免疫检测试剂中的应用
CN112946254B (zh) * 2021-01-18 2024-03-15 上海云泽生物科技有限公司 一种胶乳增强竞争免疫比浊检测方法及试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000009714A (ja) * 1998-06-10 2000-01-14 Wellcome Found Ltd:The 化合物およびその使用
US20030099636A1 (en) * 2000-06-20 2003-05-29 Epshtein Oleg Iliich Curing method for pathologic syndrome and medicinal preparation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4668640A (en) 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4492762A (en) 1981-12-11 1985-01-08 Abbott Laboratories Fluorescent polarization immunoassays
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
US4708929A (en) 1984-10-29 1987-11-24 Microgenics Corporation Methods for protein binding enzyme complementation assays
US5120653A (en) 1985-04-08 1992-06-09 Microgenics Corporation Vector comprising DNA sequence coding for enzyme-donor polypeptide
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US4847209A (en) 1987-11-09 1989-07-11 Miles Inc. Latex agglutination immunoassay in the presence of hemoglobin
US6448091B1 (en) 1988-11-03 2002-09-10 Igen International, Inc. Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection
US5798083A (en) 1988-11-03 1998-08-25 Igen International, Inc. Apparatus for improved luminescence assays using particle concentration and chemiluminescence detection
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
DE4444002A1 (de) 1994-12-10 1996-06-13 Behringwerke Ag Immunoassays für Haptene und hierfür verwendbare Haptentracer-Antikörper-Komplexe sowie Verfahren zur Herstellung derselben
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
DE60023998T2 (de) 1999-07-30 2006-08-10 Mitsubishi Chemical Corp. Immunoassay
GB0130535D0 (en) * 2001-12-20 2002-02-06 Randox Lab Ltd Haptens immunogens antibodies and conjugates to oxycodone and its metabolites
US7451190B2 (en) * 2003-11-26 2008-11-11 Yahoo! Inc. Associating multiple visibility profiles with a user of a real-time communication system
US20060115865A1 (en) 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000009714A (ja) * 1998-06-10 2000-01-14 Wellcome Found Ltd:The 化合物およびその使用
US20030099636A1 (en) * 2000-06-20 2003-05-29 Epshtein Oleg Iliich Curing method for pathologic syndrome and medicinal preparation

Also Published As

Publication number Publication date
EP1805515A2 (en) 2007-07-11
US7678551B2 (en) 2010-03-16
WO2006047451A2 (en) 2006-05-04
AU2005299537A1 (en) 2006-05-04
AU2005299537B2 (en) 2012-01-19
EP1805515A4 (en) 2009-01-21
US8592564B2 (en) 2013-11-26
CA2586511A1 (en) 2006-05-04
CA2586511C (en) 2014-11-25
JP2008518234A (ja) 2008-05-29
EP1805515B1 (en) 2014-05-21
US20060172356A1 (en) 2006-08-03
WO2006047451A3 (en) 2007-04-19
US20100209416A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
JP4902544B2 (ja) ラモトリジンの免疫アッセイ
US20060115865A1 (en) Lamotrigine analogs
US20220357331A1 (en) Levetiracetam Immunoassays
JP4990785B2 (ja) トピラメートに関する免疫アッセイ
JP2017149731A (ja) リスペリドン及びパリペリドンのハプテン
JP4435305B2 (ja) トピラメートのイムノアッセイ、並びに類似体及び抗体
US8846411B2 (en) Derivatives, reagents, and immunoassay for detecting levetiracetam
US7195882B2 (en) Monoclonal antibodies specific for buprenorphine and metabolites thereof
US20060088886A1 (en) Topiramate analogs
US20060240496A1 (en) Immunogens, derivatives and immunoassay for ethyl glucuronide

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100902

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110817

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110912

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111228

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150113

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees